{"nctId":"NCT02220907","briefTitle":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","startDateStruct":{"date":"2014-08"},"conditions":["Type 2 Diabetes Mellitus"],"count":153,"armGroups":[{"label":"Teneligliptin/Canagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Teneligliptin/Canagliflozin"]}],"interventions":[{"name":"Teneligliptin/Canagliflozin","otherNames":["Tenelia","MP-513","Canaglu","TA-7284"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women age ≥20 years old\n* HbA1c of ≥7.0% and \\<10.5%\n* FPG of ≤ 270 mg/dL\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before treatment period\n\nExclusion Criteria:\n\n* Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes\n* Patients with serious diabetic complications\n* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification\n* Patients with severe hepatic disorder or severe renal disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)","description":"The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose Level","description":"The change from baseline in fasting plasma glucose level collected at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.6","spread":"29.8"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Body Weight From Baseline","description":"The percentage change from baseline in body weight collected at Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.92","spread":"3.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":153},"commonTop":["Nasopharyngitis","Pollakiuria","Constipation","Eczema"]}}}